Program 5 : Breast cancer

Program 5 : Breast cancer


Pr Luis TEIXEIRA, was certified in internal medicine and oncology, Pierre et Marie Curie University, Paris, in 2006. He is oncologist at Hôpital Saint-Louis since 2009. He is Professor of Oncology since 2018 at Université Paris-Cité. He is currently the Head of the Breast Diseases Department « Senopole » at Saint-Louis Hospital. He authored or co-authored more than150 peer-revewed articles, mainly in the field of oncology and breast cancer.

Dr Laurence CAHEN-DOIDY, is general  surgeon, specialized in breast cancer surgery. She leads the Breast cancer surgery unit at Hôpital Saint-Louis University Hospital, Paris.


P5 Breast Cancer


Cancer Care

The Department of breast diseases (called « Sénopôle ») of Saint-Louis Hospital is a unique ambulatory structure gathering medical oncologists specialized in breast cancer and benign preneoplastic breast diseases, breast cancer surgeons, reconstructive surgeons, experts in post-tumor resection, specialists in plastic breast reconstruction, and breast radiologists with mammography and ultrasound equipment at their disposal, all working together in an integrated way. Patients are referred from the northern and eastern parts of Paris by general practitioners and community gynecologists, with a dedicated fast-track pathway allowing the diagnostic management of suspicious breast nodules in one day within the same unit and including consultation with an oncologist and a surgeon as well as radio-guided biopsies, followed by the psychologist, plastic surgeon, and radiotherapist consultations. All patient files are discussed in a multidisciplinary tumor board (MTB) gathering the Lariboisière and Saint-Louis surgical teams and the medical breast oncology team. Indeed, depending on where they live, some patients are referred to the Department of gynecological surgery of Lariboisière Hospital, where the same fast-track diagnostic pathway is also organized with dedicated mammography and ultrasound equipment and surgery consultations. The consultation to announce the histological diagnosis of cancer and the therapeutic strategy takes place at Saint-Louis hospital before the initiation of treatments, which are either loco-regional (surgery with or without radiotherapy) or systemic (neoadjuvant or adjuvant chemotherapy). A palliative care strategy is planned early on, including consultations with palliative nurses, physiotherapists, and pain doctors at the Sénopôle, according to the schedule set up by the liaison coordinating nurses. For patients with loco-regional disease, systemic treatments are administered within the Sénopôle. For patients with metastatic disease originating from Saint-Louis but also Lariboisière, Bichat, and Louis Mourier Hospitals, systemic treatments can also be administered at the ambulatory day hospital of the Saint-Louis Department of medical oncology. Reconstructive breast surgery is also offered at Saint-Louis Hospital, with a dedicated surgery department. At Bichat Hospital, which covers the northern suburbs of Paris as well as some western suburbs (92: Nanterre, Colombes), patients are referred to the Department of gynecological surgery by general practitioners and community gynecologists. A weekly MTB takes place at Bichat Hospital with the breast oncology team from the Sénopôle; surgical treatments are carried out at Bichat Hospital, while reconstructive surgery, radiotherapy, and systemic treatments are performed at Saint-Louis Hospital, with a common electronic patient file and PACS (Pictures Archiving and Communication System) allowing a perfect continuity in the patient pathway between the different hospital sites.

Thus, the three main hospital sites of the Cancer Institute AP-HP Nord (Lariboisière, Bichat & Saint-Louis Hospitals) have the second largest breast cancer activity of Paris, the first of the AP-HP network, and the third of the whole Ile-de France region, with nearly one thousand new patients per year.

Our strong translational and clinical research activity relies on a historical network gathering clinicians, onco-geneticists, pathologists, and basic science researchers:


  • Basic science:
    • INSERM U976 “Physiopathology of breast cancers” (Head: J. Lehmann-Che)


  • Our scientific topics listed below: 

1- NFAT transcription factors and cancer

We showed that depending on the NFAT isotype, the function on breast cancer cell invasion was completely opposite. Indeed, we demonstrated that NFAT1 and NFAT5 were pro-invasive (Jauliac, Nature Cell Biology 2002; Yoeli-Lerner, Mol. Cell 2005; German, Oncogene 2012; Gaudineau, J. Cell Science 2012), while NFAT3 was anti-invasive (Fougère, Oncogene 2010). We identified RERG as a functional partner of NFAT3 and showed that this complex was associated with the absence of axillary lymph node invasion (Coillard et al., Frontiers in Oncology 2022)

2- Molecular apocrine breast cancer

We participated in the French breast cancer consortium that refined the breast cancer taxonomy (Guedj, Oncogene 2012) and individualized molecular apocrine breast cancers (MABC), concerning up to 10% of breast cancer patients. MABCs are characterized by a homogeneous molecular signature of activated androgen receptor (AR) pathway in an ER-/PR- context with a HER-2-negative (corresponding to the luminal androgen receptor [LAR] subgroup defined by Lehmann, B. et al) or HER-2-positive status (Lehmann-Che Breast Cancer Res 2013)

3- Immune crosstalk in cancer progression

We study the potential role of IL-17 cytokine members in the recruitment of these cells and their putative role in the development of immunosuppressive tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC). Our goal is to evaluate the benefit of blocking IL-17 cytokine members so as to potentiate immunotherapy that is already used in breast cancer (Potteaux, J Cell Immunol 2020).

4- Translational research

We showed the dynamics of tumor metabolism by 18F-FDG uptake during neoadjuvant treatment in order to evaluate early on the response to treatment (Groheux, Eur J Cancer 2014). We also demonstrated that associating molecular tumor biomarkers to 18F-FDG uptake at baseline and in the 2nd cycle can optimize the identification of patients who do not respond to neoadjuvant therapy and need early treatment modifications.

5- In collaboration with the ECEVE | UMR S-1123, we also developed an original topic dedicated to social precariousness and inequities in health and gynecological cancers, including breast cancers.


Luis Teixeira

  • Teaching coordination:

– National inter-university degree in breast diseases

– Master 2 for advanced practice nurses: onco-hematology

  • Main teachings:

– National inter-university degree: 4–5 lectures

– National inter-university degree in cardio-oncology

National and international conferences: more than 100 conferences on medical oncology

  • Main positions within the French oncology societies:

Member of the scientific board of the CS3 (Breast Group of intergroup Unicancer)

Member of the scientific board of the immuno-oncology group


  • Cyrille Huchon & Martin Koskas

Coordinators of the training in surgery for the French Society of Gynecologic and Pelvic Surgery (Société de Chirurgie Gynécologique et Pelvienne [SCGP])

Members of the International Network on Cancer, Infertility and Pregnancy (INCIP)

Members of the European Society of Gynaecological Oncology (ESGO)